Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

(2019) Daniel Shae et al.   Nature Nanotechnology

Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1

(2018) Jing Liu et al.   BREAST CANCER RESEARCH AND TREATMENT

Cytosolic DNA Sensing in Organismal Tumor Control

(2018) Claire Vanpouille-Box et al.   CANCER CELL

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

(2018) Frederick Arce Vargas et al.   CANCER CELL

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine

(2018) Yee Sun Tan et al.   CLINICAL CANCER RESEARCH

Combination and inducible adjuvants targeting nucleic acid sensors

(2018) Burcu Temizoz et al.   CURRENT OPINION IN PHARMACOLOGY

Cancer immunotherapy beyond immune checkpoint inhibitors

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Gut microbiome modulates efficacy of immune checkpoint inhibitors

(2018) Ming Yi et al.   Journal of Hematology & Oncology

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

(2018) Jian Li et al.   Journal of Hematology & Oncology

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

(2018) Xiaolei Li et al.   Journal of Hematology & Oncology

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

(2018) Erhao Zhang et al.   Molecular Cancer

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy

(2018) Yanyu Pang et al.   Molecular Cancer

Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy

(2018) David R. Wilson et al.   Nanomedicine-Nanotechnology Biology and Medicine

Anti–CTLA-4 therapy requires an Fc domain for efficacy

(2018) Jessica R. Ingram et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer

(2018) Samuel Alvarez-Arguedas et al.   Translational Research

Targeting the IDO1 pathway in cancer: from bench to bedside

(2018) Ming Liu et al.   Journal of Hematology & Oncology

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

(2018) Yang Liu et al.   Journal of Hematology & Oncology

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

(2018) Ming Yi et al.   Molecular Cancer

Role of the cGAS–STING pathway in cancer development and oncotherapeutic approaches

(2018) Li Teng Khoo et al.   EMBO REPORTS

Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response

(2018) Assaf Marcus et al.   IMMUNITY

Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis

(2018) Nina Marí Gual Pimenta de Queiroz et al.   MOLECULAR CANCER RESEARCH

Nuclear cGAS suppresses DNA repair and promotes tumorigenesis

(2018) Haipeng Liu et al.   NATURE

Design of amidobenzimidazole STING receptor agonists with systemic activity

(2018) Joshi M. Ramanjulu et al.   NATURE

Cancer immunoediting and resistance to T cell-based immunotherapy

(2018) Jake S. O’Donnell et al.   Nature Reviews Clinical Oncology

Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles

(2018) Shannon Grabosch et al.   ONCOGENE

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

(2018) Kelsey E. Sivick et al.   Cell Reports

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

(2017) Tyrel T. Smith et al.   JOURNAL OF CLINICAL INVESTIGATION

Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes

(2017) Silvia Cerboni et al.   JOURNAL OF EXPERIMENTAL MEDICINE

New development in CAR-T cell therapy

(2017) Zhenguang Wang et al.   Journal of Hematology & Oncology

Checkpoint inhibitors in hematological malignancies

(2017) Chi Young Ok et al.   Journal of Hematology & Oncology

Chimeric antigen receptor T cells: a novel therapy for solid tumors

(2017) Shengnan Yu et al.   Journal of Hematology & Oncology

Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death

(2017) Bridget Larkin et al.   JOURNAL OF IMMUNOLOGY

Fate of micronuclei and micronucleated cells

(2017) Henning Hintzsche et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

cGAS surveillance of micronuclei links genome instability to innate immunity

(2017) Karen J. Mackenzie et al.   NATURE

Mitotic progression following DNA damage enables pattern recognition within micronuclei

(2017) Shane M. Harding et al.   NATURE

A STING-activating nanovaccine for cancer immunotherapy

(2017) Min Luo et al.   Nature Nanotechnology

Evolutionary Origins of cGAS-STING Signaling

(2017) Shally R. Margolis et al.   TRENDS IN IMMUNOLOGY

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity

(2017) Casey R. Ager et al.   Cancer Immunology Research

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

(2017) Jeremy B. Foote et al.   Cancer Immunology Research

Manipulation of Innate and Adaptive Immunity through Cancer Vaccines

(2017) Elias J. Sayour et al.   Journal of Immunology Research

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

(2017) Irene Scarfò et al.   Journal for ImmunoTherapy of Cancer

The anti-proliferative effects of type I IFN involve STAT6-mediated regulation of SP1 and BCL6

(2016) Yu-An Hsu et al.   CANCER LETTERS

Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis

(2016) Tianli Xia et al.   CANCER RESEARCH

Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells

(2016) Chih-Hang Anthony Tang et al.   CANCER RESEARCH

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

(2016) Henrique Lemos et al.   CANCER RESEARCH

Oncolytic virus therapy: A new era of cancer treatment at dawn

(2016) Hiroshi Fukuhara et al.   CANCER SCIENCE

The cGAS-STING Defense Pathway and Its Counteraction by Viruses

(2016) Zhe Ma et al.   Cell Host & Microbe

The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells

(2016) Samantha S.W. Ho et al.   IMMUNITY

Recognition of Endogenous Nucleic Acids by the Innate Immune System

(2016) Axel Roers et al.   IMMUNITY

The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons

(2016) Elizabeth. C. Carroll et al.   IMMUNITY

Antigen processing and immune regulation in the response to tumours

(2016) Emma Reeves et al.   IMMUNOLOGY

The host STING pathway at the interface of cancer and immunity

(2016) Leticia Corrales et al.   JOURNAL OF CLINICAL INVESTIGATION

The microbiome and innate immunity

(2016) Christoph A. Thaiss et al.   NATURE

Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing

(2016) Qi Chen et al.   NATURE IMMUNOLOGY

Activation of STING requires palmitoylation at the Golgi

(2016) Kojiro Mukai et al.   Nature Communications

Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis

(2016) Tianli Xia et al.   Cell Reports

Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

(2016) E. Moore et al.   Cancer Immunology Research

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer

(2016) Adrian G. Sacher et al.   JAMA Oncology

Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis

(2015) Marc Corbera-Bellalta et al.   ANNALS OF THE RHEUMATIC DISEASES

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

(2015) Zili Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

New perspectives on type I IFNs in cancer

(2015) Thomas F. Gajewski et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Cancer immunotherapy: harnessing the immune system to battle cancer

(2015) Yiping Yang   JOURNAL OF CLINICAL INVESTIGATION

Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma

(2015) Takashi Nakamura et al.   JOURNAL OF CONTROLLED RELEASE

cGAS and Ifi204 Cooperate To Produce Type I IFNs in Response toFrancisellaInfection

(2015) Kelly M. Storek et al.   JOURNAL OF IMMUNOLOGY

Chromothripsis from DNA damage in micronuclei

(2015) Cheng-Zhong Zhang et al.   NATURE

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Diverse roles of STING-dependent signaling on the development of cancer

(2015) J Ahn et al.   ONCOGENE

Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation

(2015) S. Liu et al.   SCIENCE

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

(2015) Juan Fu et al.   Science Translational Medicine

Genome-Derived Cytosolic DNA Mediates Type I Interferon-Dependent Rejection of B Cell Lymphoma Cells

(2015) Yu J. Shen et al.   Cell Reports

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma

(2014) Adeline R. Lam et al.   CANCER RESEARCH

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

(2014) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells

(2014) Jared Klarquist et al.   JOURNAL OF IMMUNOLOGY

Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF- B Activation through TBK1

(2014) T. Abe et al.   JOURNAL OF VIROLOGY

Inflammation-driven carcinogenesis is mediated through STING

(2014) Jeonghyun Ahn et al.   Nature Communications

STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment

(2014) T. Ohkuri et al.   Cancer Immunology Research

STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer

(2014) D. Chandra et al.   Cancer Immunology Research

Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase

(2013) Pu Gao et al.   CELL

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid

(2013) J. Conlon et al.   JOURNAL OF IMMUNOLOGY

cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING

(2013) Andrea Ablasser et al.   NATURE

Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP

(2013) Andrea Ablasser et al.   NATURE

Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity

(2013) John W. Schoggins et al.   NATURE

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Cyclic GMP-AMP Synthase Is an Innate Immune Sensor of HIV and Other Retroviruses

(2013) D. Gao et al.   SCIENCE

STING and the innate immune response to nucleic acids in the cytosol

(2012) Dara L Burdette et al.   NATURE IMMUNOLOGY

Type I interferon response and innate immune sensing of cancer

(2012) Mercedes B. Fuertes et al.   TRENDS IN IMMUNOLOGY

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

(2011) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

STING is a direct innate immune sensor of cyclic di-GMP

(2011) Dara L. Burdette et al.   NATURE

Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice

(2011) Abdullah S. Madhun et al.   VACCINE

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC

(2010) R. Pili et al.   CLINICAL CANCER RESEARCH

Viral apoptosis is induced by IRF-3-mediated activation of Bax

(2010) Saurabh Chattopadhyay et al.   EMBO JOURNAL

Adjuvants for cancer vaccines

(2010) Thomas W. Dubensky et al.   SEMINARS IN IMMUNOLOGY

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

(2009) Mark J. McKeage et al.   LUNG CANCER

STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

(2009) Hiroki Ishikawa et al.   NATURE

The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation

(2008) Bo Zhong et al.   IMMUNITY

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

(2008) Hiroki Ishikawa et al.   NATURE